- Price is above the Trend Line, keeping the weekly tape constructive.
EMN
NYSE
Week ended 07 Aug 2026
Weekly Investor Report
Eastman Chemical Company · Basic Materials · Specialty Chemicals
Latest close
73.64 USD
5.3%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is 3.0% above the Trend Line and sits at 71.1% of its 52-week range. The latest completed week returned 5.3%, after a 9.0% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is neither clearly cheap nor expensive. Options positioning is mixed with 25/100 conviction, while the latest news-sentiment score is 55/100.
Setup score
49
out of 100
Latest Close
73.64 USD
7 Aug 2026
1W Return
5.3%
latest completed week
4W Return
9.0%
short-term follow-through
12W Return
4.0%
quarterly tape
Trend Breadth
42.3%
22 of 52 weeks active
Volume Ratio
1.1x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Activity pressure is weak, so confirmation is not yet broad enough.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
5.3%
Latest completed week; four-week move 9.0%.
Indicator stack
23/38
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Options pressure
Mixed
25/100 conviction; expected move 4.5%.
News sentiment
55/100
50 relevant articles in the latest sentiment read.
Event risk
30 Jul
Latest stored earnings date was 30 Jul 2026.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is 3.0% above the Trend Line and sits at 71.1% of its 52-week range. The latest completed week returned 5.3%, after a 9.0% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 1.1x the 13-week average. Participation is around or above normal and provides reasonable confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.4112-week average 0.53
12-week confirmation
Trend active7/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.41Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 9.0% over four weeks, 4.0% over 12 weeks, and 25.5% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year22
Trend breadth42.3%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.67Latest activity-pressure read.
Pressure change-3.8%Four-week change in activity pressure.
Leadership-2.39Latest relative-leadership reading.
RS change73.8%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 30 Jun 2026
Field coverage 100%
Model confidence 100%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength74/100Blend of value, momentum, and quality. Underlying universe rank 27; rank 1 is best.
Value76/100Relative valuation strength. Underlying universe rank 25; rank 1 is best.
Quality21/100Profitability and accounting quality. Underlying universe rank 80; rank 1 is best.
Momentum75/100Medium-term price momentum. Underlying universe rank 26; rank 1 is best.
Growth2/100Revenue and earnings growth. Underlying universe rank 99; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework43/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 19.0x Price divided by trailing earnings.
- Price / sales
- 0.9x Market value relative to trailing revenue.
- EV / EBITDA
- 10.2x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 11.1% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 19.9% Gross profit retained from each unit of revenue.
- Operating margin
- 8.4% Operating profit retained from revenue.
- Free-cash-flow margin
- 16.3% Free cash flow generated from revenue.
- Return on invested capital
- 5.8% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- -4.5% Latest one-year revenue growth.
- EPS growth
- -46.9% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- -9.5% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 5/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 4.5% Cash dividends relative to market value.
- Buyback yield
- 1.2% Net share repurchases relative to market value.
- Shareholder yield
- 5.7% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 3.6x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Options positioningMixed
EMN shows mixed options pressure with a 25/100 conviction score, put-call volume ratio of 1.03, expected move of 4.5%, and Sharemaestro trend signal inactive.
Conviction25/100
Expected move4.5%
Put/call volume1.03
Insider activity15 / 5
15 acquisitions and 5 disposals in the latest 180-day insider tape.
Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.News sentiment55/100
Weighted news tone is neutral across 50 relevant articles.
16 positive · 30 neutral · 4 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings30 JulLatest stored earnings date was 30 Jul 2026.
Options expected move4.5%Nearest-chain priced movement where available.
52-week drawdown-9.7%Distance below the 52-week high.
13-week volatility3.2%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher10 of 2616 weeks finished lower.
Best week+9.0%Week of 27 Mar.
Worst week-6.9%Week of 6 Mar.
Latest week+5.3%Week of 7 Aug.
Shape of recent returns
Strong gains5
Modest gains5
Flat weeks0
Modest losses11
Sharp losses5
Recent vol3.2%13-week weekly-return volatility.
Base vol4.3%52-week weekly-return volatility.
Up/down split24/28Count of positive and negative weeks in the 52-week window.
Average skew4.3% / -2.7%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Basic Materials
4-week rank56 / 100
Group average8.7%
Trend breadth28.0%
Trend28.0%active weekly trend signals
MD25.0%positive activity pressure
RS42.0%positive relative leadership
Four-week leaders
IndustryUS Specialty Chemicals
4-week rank22 / 56
Group average5.9%
Trend breadth48.2%
Trend48.2%active weekly trend signals
MD50.0%positive activity pressure
RS41.1%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape44/100
Trend, activity pressure, participation, and risk combine to a 44/100 tape read.
Indicator analysis31/100Latest 12-week confirmation: trend 7/12, activity pressure 0/12, relative leadership 0/12.
Activity pressure 0.41; No reversal markers Factors60/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 29; Small Cap Core rank 18 SVQF43/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 578.5 of 1018 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Options48/100EMN shows mixed options pressure with a 25/100 conviction score, put-call volume ratio of 1.03, expected move of 4.5%, and Sharemaestro trend signal inactive.
Mixed · Options-market disagreement · Expected move 4.5% Sentiment55/100Weighted news tone is neutral across 50 relevant articles.
Enterprise value to EBIT forward of Eastman Chemical Company – NYSE:EMN Insiders15 / 515 acquisitions and 5 disposals in the latest 180-day insider tape.
Earnings30 JulLatest stored earnings date was 30 Jul 2026.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 73.64 USD | 5.3% | 71.51 USD | 77.57 USD | -0.67 | -2.39 | 6.1M | Off |
| 31 Jul 2026 | 69.95 USD | 2.6% | 71.29 USD | 77.57 USD | -0.94 | -3.98 | 7.3M | Off |
| 24 Jul 2026 | 68.20 USD | -0.6% | 71.05 USD | 77.60 USD | -1.05 | -5.31 | 6.8M | Off |
| 17 Jul 2026 | 68.60 USD | 1.5% | 70.85 USD | 77.66 USD | -0.89 | -5.80 | 5.6M | Off |
| 10 Jul 2026 | 67.57 USD | -1.9% | 70.63 USD | 77.71 USD | -0.65 | -9.13 | 5.8M | Off |
| 3 Jul 2026 | 68.86 USD | -2.6% | 70.47 USD | 77.77 USD | -0.33 | -6.75 | 6.6M | On |
| 26 Jun 2026 | 70.71 USD | -2.5% | 70.16 USD | 77.82 USD | -0.27 | -2.74 | 6.6M | On |
| 19 Jun 2026 | 72.49 USD | -2.6% | 69.80 USD | 77.84 USD | -0.28 | -3.08 | 5.4M | On |
| 12 Jun 2026 | 74.39 USD | 4.7% | 69.29 USD | 77.82 USD | -0.30 | -0.06 | 4.0M | On |
| 5 Jun 2026 | 71.05 USD | -5.3% | 68.75 USD | 77.81 USD | -0.48 | -4.42 | 5.7M | On |
| 29 May 2026 | 75.03 USD | 2.4% | 68.35 USD | 77.81 USD | -0.39 | -2.13 | 4.2M | On |
| 22 May 2026 | 73.30 USD | 3.5% | 67.76 USD | 77.79 USD | -0.28 | -3.50 | 7.2M | On |
| 15 May 2026 | 70.79 USD | -2.8% | 67.34 USD | 77.78 USD | -0.32 | -6.60 | 4.3M | On |
| 8 May 2026 | 72.84 USD | -5.0% | 66.95 USD | 77.79 USD | -0.15 | -4.35 | 6.3M | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.